81
edits
Supply Chain Issues: Difference between revisions
no edit summary
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
Introduction | |||
Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y | The COVID-19 pandemic precipitated a global disruption of supply chains and led to significant global supply shortages in various medicines and health-related products. Shortages and struggles for access disproportionately affected vulnerable populations, including those with chronic illnesses, low-income individuals, and marginalised communities. | ||
The situation exacerbates existing global health inequities. <ref>Haldane, V., De Foo, C., Abdalla, S.M. et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med 27, 964–980 (2021). https://doi.org/10.1038/s41591-021-01381-y</ref> Whilst shortages and uncertain medical stocks, and counterfeit medical essentials, are problems across the board. Developed countries experience disruptions in supply chains for medications that were previously available, whilst lower income countries face chronic shortages and limited access to essential drugs, and others historically lacking access to certain essential medications. | |||
===Ongoing Supply Chain Challenges=== | ===Ongoing Supply Chain Challenges=== | ||
| Line 44: | Line 46: | ||
Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production. | Routine vaccines, such as flu vaccines, were in short supply due to the focus and attention shifting to COVID-19 vaccine production. | ||
==Citations== | ==Citations== | ||
<references/> | |||